Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE III ctDNA-guided adjuvant chemotherapy in stage III colorectal cancer
2025-521045-24-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of irinotecan, fluorouracil, folinic acid, oxaliplatin and capecitabine in colorectal cancer (CRC) (3 arms), sponsored by Unicancer. Primary endpoint: 3-year disease-free survival rate. Planned start Jul 2026; status: authorised.
02
Drugs
irinotecanfluorouracilfolinic acidoxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-521045-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521045-24-00.